ORPHA:206569
Immune-mediated necrotizing myopathy
Also known as: AINM · Autoimmune necrotizing myositis · IMNM · NAM · Necrotizing autoimmune myositis
Publications
1,727
89.6th percentile
Trials
13
Interventional, condition-specific
Researchers
1,146
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare form of inflammatory characterized by acute or subacute, severe, symmetrical, proximal muscle weakness usually associated with muscle-specific antibodies (anti-HMGCR or anti-SRP). Histopathological characteristics include myocyte necrosis and regeneration without significant inflammation, and C5b-9 deposition on non-necrotic myofibers.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016098
- UMLS:C3267047
Additional Mondo synonyms (4)
anti-HMG-CoA myopathy · anti-SRP myopathy · autoimmune necrotizing myositis · immune myopathy with myocyte necrosis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,727 matched papers (1,565 in last 10 years) Source
- Phenotype characterisedPresent
24 HPO annotations (e.g. Myopathy; Elevated circulating creatine kinase activity; EMG: myopathic abnormalities) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
13 matched on ClinicalTrials.gov (8 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
24
Associated phenotypes · MONDO:0016098
- Myopathy
- Elevated circulating creatine kinase activity
- EMG: myopathic abnormalities
- Muscle fiber necrosis
- Autoimmune antibody positivity
Showing 5 of 24 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,727
1,727 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,727 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,565 in the last 10 years · medium confidence · 89.6th percentile (publications denominator)
Phrase hits: 1,727 · MeSH hits: 0
Who's working on it?
1,146
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Nishino I6 papers · 2026
Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
Papers in Europe PMC - 02Stenzel W5 papers · 2026
Department of Neuropathology, Charité Medicine University, 10117 Berlin, Germany.
Papers in Europe PMC - 03Yang L5 papers · 2026
Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Papers in Europe PMC - 04Yang M5 papers · 2026
Department of Neurology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Papers in Europe PMC - 05Aggarwal R4 papers · 2026
Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Papers in Europe PMC - 06Allenbach Y4 papers · 2026
Sorbonne University, INSERM, Center of Research in Myology, UMRS 974, Paris, 75013, France.
Papers in Europe PMC - 07Benveniste O4 papers · 2026
Sorbonne University, INSERM, Center of Research in Myology, UMRS 974, Paris, 75013, France. olivier.benveniste@aphp.fr.
Papers in Europe PMC - 08Gao H4 papers · 2026
Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Papers in Europe PMC - 09Ge H4 papers · 2026
Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Papers in Europe PMC - 10Li Q4 papers · 2026
Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Number 37 Guoxue Alley in the Wuhou District, Chengdu, 610041, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
13
interventional trials for this specific condition
13 interventional trials matched this specific condition name; 8 currently recruiting in our sample.
Data as of 11 September 2026
13 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 93.5th percentile).
medium confidence · 93.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
13 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06154252·RECRUITING·RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Not reviewed·Conditions: Idiopathic Inflammatory Myopathy · Dermatomyositis · Anti-Synthetase Syndrome · Immune-Mediated Necrotizing Myopathy·Matched via name phrase
- NCT06371417·RECRUITING·Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Not reviewed·Conditions: Antiphospholipid Syndrome (APS) · Bullous Pemphigoid (BP) · Behçet's Syndrome (BS) · Dermatomyositis (DM)·Matched via name phrase
- NCT07103746·RECRUITING·Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
Not reviewed·Conditions: Autoimmune Disorders·Matched via name phrase
- NCT07676266·NOT YET RECRUITING·A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Not reviewed·Conditions: Multiple Sclerosis (MS) · Myasthenia Gravis (MG) · Neuromyelitis Optica Spectrum Disorder · Systemic Lupus Erythematosus·Matched via name phrase
- NCT06599697·RECRUITING·The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy
Not reviewed·Conditions: Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy·Matched via name phrase
- NCT06249438·RECRUITING·A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Not reviewed·Conditions: Systemic Lupus Erythematosus (SLE) · Immune-mediated Necrotizing Myopathy (IMNM) · Neuromyelitis Optica Spectrum Disorders (NMOSD) · Multiple Sclerosis (MS)·Matched via name phrase
- NCT05979441·ENROLLING BY INVITATION·A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Not reviewed·Conditions: Myositis · Active Idiopathic Inflammatory Myopathy · Dermatomyositis · Polymyositis·Matched via name phrase
- NCT06723106·ENROLLING BY INVITATION·Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
Not reviewed·Conditions: Antiphospholipid Syndrome (APS) · Bullous Pemphigoid (BP) · Behçet's Syndrome (BS) · Dermatomyositis (DM)·Matched via name phrase
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07374107·RECRUITING·MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
Not reviewed·Conditions: IBM · IIM · Myositis · Inflammatory Myopathy·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 9 · after dedupe 9 · already on CT.gov 1 · kept 0 · parent 0 · uncertain 8 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (8)
- isrctn·ISRCTN44828082·No longer recruiting·A phase II proof of concept study to evaluate the efficacy and safety of daxdilimab in participants with dermatomyositis (DM) or anti-synthetase inflammatory myositis (ASIM)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN98762360·No longer recruiting·A study of nipocalimab in participants with active idiopathic inflammatory myopathies
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN35925199·No longer recruiting·The effect of physical activity interventions on inflammatory muscle disorders
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11520709·Stopped·Efficacy and safety of Octanorm in patients with dermatomyositis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN32265704·No longer recruiting·Study regarding the safety of Gammanorm in autoimmune diseases
skipped — LLM skipped (--skip-llm)
- ctis·2025-521145-24-01·Authorised·A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or Active Juvenile Idiopathic Inflammatory Myopathy
skipped — LLM skipped (--skip-llm)
- ctis·2024-511346-39-00·Authorised, recruiting·Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
skipped — LLM skipped (--skip-llm)
- ctis·2023-507692-21-00·Authorised, ongoing·Phase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Immune-mediated necrotizing myopathy — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Immune-mediated necrotizing myopathy" OR "Autoimmune necrotizing myositis" OR "Necrotizing autoimmune myositis" OR "anti-HMG-CoA myopathy" OR "anti-SRP myopathy" OR "immune myopathy with myocyte necrosis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Immune-mediated necrotizing myopathy" OR "Autoimmune necrotizing myositis" OR "Necrotizing autoimmune myositis" OR "anti-HMG-CoA myopathy" OR "anti-SRP myopathy" OR "immune myopathy with myocyte necrosis"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 13 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: AINM; IMNM; NAM
Confidence reasoning
- Preferred label is multi-word and distinctive
- 3 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T09:20:05.254Z
